Corbus Pharmaceuticals (CRBP) vs PMV Pharmaceuticals (PMVP)
Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Oct 9, 2026.
Summary
PMV Pharmaceuticals (PMVP) has outperformed Corbus Pharmaceuticals (CRBP) over the past year, gaining 4.9% versus a loss of 60.7%. Over five years, CRBP leads with a -82.8% price change compared with -93.8% for PMVP. PMV Pharmaceuticals is the larger company by market cap ($112.5 million vs $101.9 million), about 1.1 times the size.
Summary generated from market data by MetaCap's automated system. Methodology
Relative performance
Percent change in share price from the first common trading day shown; excludes dividends.
Head-to-head
| Metric | CRBP | PMVP |
|---|---|---|
| Share price | $5.27 | $1.49 |
| Market cap | $101.93M | $112.51M |
| 1-day change | -4.01% | -0.67% |
| YTD return | -35.26% | +19.20% |
| 1-year return | -60.73% | +4.93% |
| 5-year return | -82.78% | -93.78% |
| EPS (TTM) | $-6.11 | $-1.42 |
| Dividend yield | 0.00% | 0.00% |
| Annual dividend | $0.00 | $0.00 |
| 52-week high | $20.56 | $1.91 |
| 52-week low | $5.13 | $1.02 |
| Distance from 52-week high | -74.37% | -21.99% |
| Analyst consensus | strong_buy | none |
| Avg. price target upside | +545.73% | +181.88% |
| Average volume | 756.54K | 661.39K |
| Shares outstanding | 19.34M | 75.51M |
| Employees | 36 | 54 |
| Sector | Health Care | Health Care |
| Industry | Biotechnology: Pharmaceutical Preparations | Biotechnology: Pharmaceutical Preparations |
Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.
Key differences
- PMVP has outperformed CRBP by 65.7 percentage points over the past year.
About Corbus Pharmaceuticals
CRBP stock →Corbus Pharmaceuticals Holdings, Inc., a clinical stage company, develops and commercializes therapeutics for cancer and obesity. Its pipeline includes CRB-701, an antibody drug conjugate that targets the expression of Nectin-4 on cancer cells to release a cytotoxic payload of monomethyl auristatin E; and CRB-913, a peripherally restricted cannabinoid type-1 receptor inverse agonist for the treatment of obesity.
Health Care · Biotechnology: Pharmaceutical Preparations · 36 employees
About PMV Pharmaceuticals
PMVP stock →PMV Pharmaceuticals, Inc., a precision oncology company, engages in the discovery and development of small molecule therapies targeting p53 mutations and other p53-related cancers in the United States. It develops rezatapopt, a selective structural corrector of p53 Y220C mutations in Phase 2 clinical trials for tumor agnostic diseases.
Health Care · Biotechnology: Pharmaceutical Preparations · 54 employees
CRBP vs PMVP FAQ
Which is bigger, Corbus Pharmaceuticals or PMV Pharmaceuticals?
PMV Pharmaceuticals (PMVP) is larger, with a market capitalization of $112.51M compared with $101.93M for Corbus Pharmaceuticals (CRBP).
Which stock has performed better over the past year, CRBP or PMVP?
PMVP returned +4.93% over the past 12 months, compared with -60.73% for CRBP (price return, excluding dividends). Past performance does not predict future results.
Are Corbus Pharmaceuticals and PMV Pharmaceuticals in the same industry?
Yes. Both are classified in the Biotechnology: Pharmaceutical Preparations industry within the Health Care sector.